Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. More Details
High growth potential with excellent balance sheet.
Share Price & News
How has Medical Developments International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MVP has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MVP exceeded the Australian Pharmaceuticals industry which returned -31.2% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned -9.2% over the past year.
Price Volatility Vs. Market
How volatile is Medical Developments International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StUpdate: Medical Developments International (ASX:MVP) Stock Gained 78% In The Last Five Years
2 months ago | Simply Wall StEstimating The Intrinsic Value Of Medical Developments International Limited (ASX:MVP)
3 months ago | Simply Wall StWhat Kind Of Investors Own Most Of Medical Developments International Limited (ASX:MVP)?
Is Medical Developments International undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MVP (A$5.32) is trading above our estimate of fair value (A$0.35)
Significantly Below Fair Value: MVP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MVP is poor value based on its PE Ratio (920.7x) compared to the XO Pharmaceuticals industry average (38.5x).
PE vs Market: MVP is poor value based on its PE Ratio (920.7x) compared to the Australian market (20.8x).
Price to Earnings Growth Ratio
PEG Ratio: MVP is poor value based on its PEG Ratio (12.8x)
Price to Book Ratio
PB vs Industry: MVP is overvalued based on its PB Ratio (8.1x) compared to the AU Pharmaceuticals industry average (3.4x).
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP's forecast earnings growth (72.1% per year) is above the savings rate (2.3%).
Earnings vs Market: MVP's earnings (72.1% per year) are forecast to grow faster than the Australian market (18.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MVP's revenue (28.2% per year) is forecast to grow faster than the Australian market (5% per year).
High Growth Revenue: MVP's revenue (28.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (10.7%).
How has Medical Developments International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP has a high level of non-cash earnings.
Growing Profit Margin: MVP's current net profit margins (1.7%) are lower than last year (5%).
Past Earnings Growth Analysis
Earnings Trend: MVP's earnings have declined by 18.3% per year over the past 5 years.
Accelerating Growth: MVP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MVP had negative earnings growth (-63.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (117.8%).
Return on Equity
High ROE: MVP's Return on Equity (0.9%) is considered low.
How is Medical Developments International's financial position?
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$26.0M) exceed its short term liabilities (A$8.2M).
Long Term Liabilities: MVP's short term assets (A$26.0M) do not cover its long term liabilities (A$33.2M).
Debt to Equity History and Analysis
Debt Level: MVP's debt to equity ratio (0.2%) is considered satisfactory.
Reducing Debt: MVP's debt to equity ratio has reduced from 6.4% to 0.2% over the past 5 years.
Debt Coverage: MVP's debt is well covered by operating cash flow (189%).
Interest Coverage: MVP earns more interest than it pays, so coverage of interest payments is not a concern.
What is Medical Developments International current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MVP is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. R. Max Johnston has been a Non-Executive Director of Medical Developments International Limited since November 05, 2012 and serves as its Acting Chief Executive Officer. He served as the President and ...
|Acting CEO & Non-Executive Director||no data||AU$60.00k||0.061% |
|CFO & Company Secretary||3yrs||AU$286.91k||no data|
|Head of Sales & Marketing||1.25yrs||no data||no data|
|Head of Human Resources||1.25yrs||no data||no data|
|Chief Scientific Officer||1.25yrs||no data||no data|
|Head of Medical Affairs||2.17yrs||no data||no data|
|Head of Regulatory Affairs||1.92yrs||no data||no data|
|Head of Quality||1.75yrs||no data||no data|
|Head of Project Management Office||1.25yrs||no data||no data|
|Head of Production||0.25yr||no data||no data|
|Head of Europe||0.17yr||no data||no data|
Experienced Management: MVP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Acting CEO & Non-Executive Director||no data||AU$60.00k||0.061% |
|Non-Executive Director||no data||no data||no data|
|Non-Executive Director||5.83yrs||AU$60.00k||0.40% |
|Non Executive Chairman||17.08yrs||AU$95.00k||13.13% |
|Non-Executive Director||7.08yrs||AU$60.00k||0.032% |
|Non-Executive Director||0.42yr||AU$5.00k||no data|
Experienced Board: MVP's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MVP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medical Developments International Limited's company bio, employee growth, exchange listings and data sources
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$355.679m
- Shares outstanding: 65.62m
- Website: https://medicaldev.com
Number of Employees
- Medical Developments International Limited
- 4 Caribbean Drive
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MVP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2003|
|MDDV.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2003|
|MVP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2003|
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical De ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/30 10:43|
|End of Day Share Price||2020/10/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.